Expertise in
5
conditions

Liqun P. Zou

Chengdu, CN 
Expertise in
5
conditions
Chengdu, CN 
OverviewLocationsClinical Research

Overview

Liqun Zou practices in Chengdu, China. Zou is highly rated in 5 conditions, according to our data. Their top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

Their clinical research consists of co-authoring 103 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Chengdu, China
Other Locations
China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib SandwichWith Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib SandwichWith Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug
Study Drug: Sintilimab
Study Phase: Phase 2
View 3 Less Clinical Trials

103 Total Publications

The mediating effect of job burnout between workplace violence and sleep disorders among emergency department nurses.
The mediating effect of job burnout between workplace violence and sleep disorders among emergency department nurses.
Journal: Frontiers in public health
Published: June 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zou's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile